Related Experiment Video

Updated: Aug 12, 2026

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
08:01

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

[Curative treatment of invasive aspergillosis]

B Dupont1

  • 1Institut Pasteur, Hôpital et Unité de Mycologie, Paris, France.

Pathologie-Biologie
|September 1, 1994
PubMed

Insights

Invasive aspergillosis treatment is challenging. Itraconazole offers a potentially safer alternative to amphotericin B, but more comparative studies are needed for optimal patient care.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Context:

  • Invasive aspergillosis is a serious opportunistic infection in immunocompromised individuals.
  • Current treatment options, intravenous amphotericin B and itraconazole, have limitations.
  • Treatment strategies must be tailored to the diverse clinical presentations of the infection.

Purpose:

  • To review the current treatment landscape for invasive aspergillosis.
  • To compare the efficacy and toxicity profiles of amphotericin B and itraconazole.
  • To identify areas for future research and clinical trials.

Summary:

  • Amphotericin B is the standard treatment but carries significant toxicity, especially at high doses, with suboptimal outcomes in certain populations like bone marrow transplant recipients.
  • Lipid formulations of amphotericin B show reduced toxicity, but data on their efficacy is limited.
  • Itraconazole, an effective anti-Aspergillus agent with lower toxicity, exhibits variable absorption, making it a potential alternative or first-line option in specific cases.
  • Further research, particularly comparative studies involving granulopenic patients and new antifungal agents, is crucial.

Impact:

  • Highlights the need for personalized treatment approaches for invasive aspergillosis.
  • Emphasizes the potential role of itraconazole as a viable alternative to amphotericin B.
  • Underscores the necessity for comparative clinical trials to guide optimal antifungal selection.
  • Suggests that adjunct therapies like hematopoietic growth factors and surgery may improve patient outcomes.

More Related Videos

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Fungal Phylum Ascomycota01:28

Fungal Phylum Ascomycota

Phylum Ascomycota, a major division within the subkingdom Dikarya, comprises a diverse range of fungal species, including both unicellular yeasts and filamentous molds such as Aspergillus and Penicillium. These fungi thrive in a variety of habitats, from aquatic ecosystems to terrestrial environments, playing crucial ecological and economic roles.Morphology and ReproductionThe defining characteristic of Ascomycetes, commonly referred to as sac fungi, is the ascus—a sac-like structure that...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...